Skip to content

KalVista Pharmaceuticals, Inc.

KALV

CIK 0001348911

← back to feed
Revenue (TTM)
$57.56M
+1,183.4% YoY Q1 May 2026
Net Income (TTM)
−$190.66M
+40.3% YoY Q1 May 2026
EPS Diluted (TTM)
−$3.45
+45.0% YoY Q1 May 2026
Gross Margin
94.6%
Q1 May 2026
Operating Margin
-309.6%
Q1 May 2026
Net Margin
-331.3%
Q1 May 2026
Free Cash Flow (TTM)
−$157.46M
Q1 May 2026
Cash
$213.77M
Q1 May 2026
Total Debt
$172.21M
Q1 May 2026
Shares Outstanding
53.24M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings